BeOne Medicines (ONC) Non-Current Debt (2015 - 2026)

BeOne Medicines (ONC) has reported Non-Current Debt for 12 consecutive years, with $842.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Debt rose 426.31% year-over-year to $842.9 million; the TTM figure through Mar 2026 stood at $842.9 million (up 426.31% YoY), while the FY2025 annual figure was $961.9 million, up 477.78% from the prior year.
• Non-Current Debt retreated to $842.9 million in Q1 2026 per ONC's latest filing, from $961.9 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $961.9 million in Q4 2025 and bottomed at $139.6 million in Q3 2025.
• Historically, Non-Current Debt has averaged $271.0 million across 5 years, with a median of $199.0 million in 2024.
• On a YoY basis, Non-Current Debt climbed as much as 477.78% in 2025 and fell as far as 25.57% in 2025.
• BeOne Medicines' Non-Current Debt stood at $209.1 million in 2022, then slipped by 5.51% to $197.6 million in 2023, then decreased by 15.75% to $166.5 million in 2024, then soared by 477.78% to $961.9 million in 2025, then retreated by 12.37% to $842.9 million in 2026.
• Business Quant data shows ONC's Non-Current Debt at $842.9 million in Q1 2026, $961.9 million in Q4 2025, and $139.6 million in Q3 2025.